[Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis]

Jpn J Antibiot. 2014 Jun;67(3):205-10.
[Article in Japanese]

Abstract

Treatment for chronic pulmonary aspergillosis is difficult and frequently is required for prolong period. In outpatients setting, only voriconazole and itraconazole could be used. Since liposomal amphotericin B (L-AMB) demonstrated prolonged half-time, we have investigated the feasibility of L-AMB in outpatient setting. Three cases of chronic pulmonary aspergillosis were treated with intermittent administration of 2.5 mg/kg of L-AMB twice weekly for one month in outpatient settings. Improve of symptoms was attained in 2 of 3 cases. Improvement of chest images were in 2 of 3, improvement of laboratory test were in 2 of 3. Adverse events were only fatigue and short period of fever. No recurrence of pulmonary aspergillosis has been found after treatment. Intermittent administration of L-AMB in outpatient settings could be an option for pulmonary aspergillosis.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Amphotericin B / administration & dosage*
  • Amphotericin B / adverse effects
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / adverse effects
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Pilot Projects
  • Pulmonary Aspergillosis / drug therapy*

Substances

  • Antifungal Agents
  • liposomal amphotericin B
  • Amphotericin B